Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.103
Peer-review started: November 3, 2023
First decision: November 16, 2023
Revised: November 29, 2023
Accepted: January 2, 2024
Article in press: January 2, 2024
Published online: January 27, 2024
Processing time: 83 Days and 2.9 Hours
Endoscopic retrograde cholangiopancreatography (ERCP) is a commonly used modality for the treatment of choledocholithiasis, with a stone clearance rate of up to 95%; however, the recurrence rate has not decreased. Ursodeoxycholic acid (UDCA) is a postoperative drug used to prevent stone recurrence; however, its effectiveness is yet to be explored. Therefore, this study focused on biliopancreatic surgery to investigate the interventional effect of UDCA after ERCP for choledocholithiasis and analyze the risk factors for recurrence.
Recurrence of choledocholithiasis after ERCP brings pain to patients; therefore, this paper retrospectively analyzes the intervention effect of UDCA after ERCP for choledocholithiasis and the risk factors of recurrence, in order to provide a new research direction and reference for the prevention and treatment of stone recurrence.
To analyze the intervention effect of the prophylactic use of UDCA after ERCP and the influencing factors of postoperative recurrence, and to explain the mechanism of action.
The clinical records of 100 cases after ERCP were retrospectively selected, the therapeutic effects of non-UDCA and UDCA after ERCP and their effects on liver function were evaluated, and the rate of relapse within the two patient populations was compared. The risk factors for relapse were determined.
The clinical efficacy rates were 92.45% in UDCA group and 78.72% in control groups. The factors associated with recurrence after ERCP for choledochal stones included parapapillary diverticulum, number of stones > 3, positive bile culture, postoperative UDCA, and maximum stone diameter.
The administration of UDCA to patients with common bile duct stones following ERCP can enhance liver function recovery and effectively decrease relapse.
Future studies should explore the relevant mechanisms of action of UDCA treatment and construct a risk prediction model to evaluate its clinical benefits.